BIBLIOGRAFIA
1. Drosos AA, Andonopoulos AP et al. Prevalence of Primary Sjogren’s Syndrome in an elderly population. Br J Rheumatol. 1988; 27: 123-7 2. Robbins. Basic Pathology 7° edizione. ISBN 1-4160-2973-7.
3. Bloch KJ, Buchanan WW, Wohl MJ, Bunim JJ: Sjogren Syndrome: a clinical, pathological, and serological study of sixty-two cases. Medicine (Baltimore) 1965, 44,187.
4. Gannot G, Lancaster HE, Fox PC. Clinical course of primary Sjogren’s Syndrome: salivary, oral, and serologic aspects. J Rheumatol 2000; 27: 1905-9
5. Shearn MA, Tu WH: Nephrogenic diabetes insipidus and other defect of renal tubular functions in Sjogren Syndrome. Am. J. Med. 1965, 39,312
6. Baldini C, Tavoni A, Merlini G, Sebastiani M, Bombardieri S. Sindrome di Sjogren primitiva: descrizione clinica e sierologica di una casistica monocentrica. Reumatismo, 2005; 57(4): 256-261
7. Tsifetaki N, et al. Ann Rheum Dis 2003; 62:1204-1207
8. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, Daniels TE, Fox PC, Fox RI, Kassan SS, Pillemer SR, Talal N, Weisman MH; European Study Group on Classification Criteria for Sjogren's Syndrome. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61(6):554-8
9. Fox RI, Tornwall J, Michelson P. Current Issues in the diagnosis and treatment of Sjogren’s Syndrome. Cur Opin Rheumatol 1999; 11:364-71
10. Moutsopoulos HM, Chused TM, Mann DL, Klippel JH, Fauci AS, Frank MM, Lawley TJ, Hamburger MI: Sjogren Syndrome (sicca syndrome): Current Issue.Ann. Intern. Med. 1980, 92 ,212
11. Ramos-Casals M, Tzioufas AG, Stone JH, Siso A, Bosch X. Treatment of primary Sjogren syndrome: a systematic review. JAMA. 2010;304(4):452-60.
12. Sall K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease: CsA Phase 3 Study Group. Ophthalmology. 2000;107(4):631-639.
13. Barber LD, Pflugfelder SC, Tauber J, Foulks GN. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years.
Ophthalmology. 2005;112(10):1790-1794.
14. Stevenson D, Tauber J, Reis BL. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose ranging, randomized trial: the Cyclosporin A Phase 2 Study Group. Ophthalmology. 2000;107(5):967-974.
15. Kim EC, Choi JS, Joo CK. A comparison of vitamin A and cyclosporine A 0.05% eye drops for treatment of dry eye syndrome.
Am J Ophthalmol. 2009;147(2):206-213.
16. Sall KN, Cohen SM, Christensen MT, Stein JM. An evaluation of the efficacy of a cyclosporine-based dry eye therapy when used with marketed artificial tears as supportive therapy in dry eye. Eye
Contact Lens. 2006;32(1):21-26.
17. Roberts CW, Carniglia PE, Brazzo BG. Comparison of topical cyclosporine, punctal occlusion, and a combination for the treatment of dry eye. Cornea. 2007;26(7):805-809.
18. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (DEWS) 2007. Ocul. Surf. 2007 Apr; 5(2): 75-92
19. Yoon KC, Jeong IY, Park YG and Yang SY, Interleukin-6 and tumor necrosis factor-alpha levels in tears of patients with dry eye syndrome. Cornea. 2007; 26:431-7
20. Jones DT, Monroy D, Ji Z, Atherton SS and Pflugfelder SC, Sjogren’s Syndrome: cytokine and Epstein-Barr viral gene
expression within the conjunctival epithelium. Invest Ophthalmol Vis Sci. 1994; 35:3493-504
21. Begley CG, Chalmers RL, Abetz L, et al, The relationship between abitual patients-reported symptoms and clinical signs among patients with dry eye of varying severity. Invest Ophthalmol Vis Sci 2003; 44:4753-61
22. Donnenfeld E, Pflugfelder SC. Topical ophthalmic cyclosporine: pharmacology and clinical uses. Surv Ophthalmol. 2009;54(3):321-38.
23. Kojima T, Matsumoto Y, Dogru M, Tsubota K. The application of in vivo laser scanning confocal microscopy as a tool of conjunctival in vivo cytology in the diagnosis of dry eye ocular surface disease. Mol Vis. 2010;16:2457-64.
24. Villani E, Galimberti D, Viola F, Mapelli C, Ratiglia R. The cornea in Sjogren's syndrome: an in vivo confocal study. Invest Ophthalmol Vis Sci. 2007;48(5):2017-22.
25. Oliveira-Soto L, Efron N. Morphology of corneal nerves using confocal microscopy. Cornea. 2001;20(4):374-84.
26. Lemp MA: Report of the National Eye Institute/ Industry Workshop on Clinical trials in Dry eyes. CLAO J 1995; 21: 221-32.
27. Chodosh J, Dix R, Howell RC, Dtroop WG, TsengSC: Staining characteristics and antiviral activity of sulphorodamine B and lissamine green B. Invest Ophthalmol VisSci 1994; 35:1046-58
28. Tuominen IS, Konttinen YT, Vesaluoma MH, Moilanen JA, Helinto M, Tervo TM. Corneal innervation and morphology in primary
Sjogren's syndrome. Invest Ophthalmol Vis Sci. 2003;44(6):2545-9. 29. Benitez del Castillo JM, Wasfy MA, Fernandez C, Garcia-Sanchez
J. An in vivo confocal masked study on corneal epithelium and subbasal nerves in patients with dry eye. Invest Ophthalmol Vis Sci. 2004;45(9):3030-5.
